Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its portfolio includes two products, daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.
Investors have been bullish on biotech, in the hope that companies will soon come up with a treatment, cure, or vaccine for Covid-19. But there’s more to biotech than the coronavirus, and even though these ETFs have risen, they could have farther to go.
Ladies and gentlemen, thank you for standing by, and welcome to Genmab's First Quarter Report 2020 Conference Call. Genmab is not under an obligation to update statements regarding the future nor to confirm such statements in relation to actual results, unless this is required by law. Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward.
NEW YORK, NY / ACCESSWIRE / May 6, 2020 / Genmab A/S (NASDAQ:GMAB) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 6, 2020 at 6:00 PM Eastern Time. ...